DAFTAR PUSTAKA

Adams,M.,et.al., Dendritic cell (DC) based therapy for cervicalcancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C12U] (Ampligenő), *Vaccine* Volume 21, Issues 7-8, Pages 787-790.

Albert, A.A, 1943, An Inductive Proof of Descartes' Rule of Sign, *The American Mathematical Monthly*, Vol.50, No. 3, pp. 178-180

Arrowsmith, D.K., Place, C.M., 1992, *Dynamical Systems, Diferretial, maps and chaotic behaviour*, Chapman & Hall, London.

Ault, K.A.,2006, Clinical Study, Epidemiology and Natural History of Human Papillomavirus Infections in the Female Genital Tract, *Infectious Diseases in Obstetrics and Gynecology*, Volume 2006, Article ID 40470, Pages 1-5.

Aguda B.D et.al., 2008, MicroRNA Regulation of a Cancer Network : Concequences of feedback loops involving miR-17-92, E2F, and Myc. *PNAS* vol. 105, no. 50, page 19678-19683.

Aziz, M.F. dkk., 2006, *Onkologi Ginekologi*, Yayasan Bina Pustaka Sarwono Prawirihardjo, Jakarta.

Bakri,T.,et.al., 2004, Parametric Excitation in Nonlinear Dynamics, *International Journal of Non-Linear Mechanics*, Vol. 39, pages 311-339.

Barnabas, R.V., et.al. 2006, Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination : Mathematical Modelling analyses, *PLOS Medicine*, volume 3, Issue 5. pages 0624-0632.

Bonhoeffer, S., et. al., 1997, Virus Dynamics and drug therapy, *Proc. Natl. Acad. Sci.*, Vol. 94, pages 6971-6976.

Bosch, F.X, et.al., 1995, Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Prespective, *Journal of the National Cancer Institute*, Vol. 87, No. 11, pages 796-802.

Bosch, F.X, et.al., 2002 ,The Causal Relation Betwen of Human Papillomavirus and Cervical Cancer, *J Clin Pathol*, 55, pages 244-265.

Castiglione, F., Piccoli, B., 2007, Cancer immunotherapy, mathematical modeling and optimal control, *Journal of Theoretical Biology*, 247, pages 723-732.

Cirelli, R., Tyring, S.K., 1994, Interferons in human papillomavirus infections, *Antiviral Research*, 24, pp.191-204.

Diaz-Arratia, C.,Arany,I.,Robazetti,S.C.,Dinh,T.V., Gatalica, Z., Trying, S.K., Hannigan, E., 2001, Clinical and Molecular Responses in High-Grade Intraepithelial Neoplasia Treated with Topical Imiquimod 5%, *Clinical Cancer Research*, vol. 7, pp.3031-3033.

Diekmann, O., Heesterbeek,J.A.P., 2000, *Mathematical Epidemiology of Infectious Diseases*, John Willey & Son, LTD, New York.

Dumrongpokaphan, et.al., 2007, An Intracellular Delay-Differential Equation Model of the HIV Infection and Immune Control, *Math. Model. Nat. Phenom.*, Vol.2, No. 1, pages 84-112.

Elbasha, et.al., 2007, Model for Assessing Human Papillomavirus Vaccination Strategies, *Emerging Infectious Diseases*, Vol 13, No. 1, pages 28-41.

Elbasha, E.H, 2008, Global Stability of Equilibria in a Two-Sex HPV Vaccination Model, *Bulletin of Mathematical Biology*, Vol. 70, pages 894-909.

Forde J dan Nelson P (2004) Application of Sturm sequence to bifurcation analysis of delay differential equation models, *J of Math Anal Appl* 300: 273–284. doi: 10.1016/j.jmaa.2004.02.063

Garcea, R.L., Di Maio, D., 2007, *The Papillomaviruses*, Springer, New York.

Globocan 2008, 2010, http://globocan.iarc.fr/ , Download Maret 2012.

Globocan 2012, 2015, http://globocan.iarc.fr/ , Download Agustus 2015.

Goldhaber-Fiebert, J.D., et.al., 2008, Cost-effectiveness of cervical cancer screening with Human Papillomavirus DNA testing and HPV-16,18 vaccination. *Journal of National Cancer Institute*, Vol. 100, Issue 5, pages 308-320.

Goldie, S.J., et.al., 2004, Projected Clinical Benefits and cost-effectiveness of a Human Paillomavirus 16/18 vaccine, *Journal of National Cancer Institute*, Volume 96, No. 8, pages 604-615.

Goodwin, B.C., 1963, *Temporal Organization in Cells; A Dynamic Theory of Cellular Control Processes*, Academic Press, London.

Hebner, C.M., and Laimins, L.A., 2006, Human Papillomaviruses: Basic Mechanisms of Pathogenesis and Oncogenicity, *Reviews in Medical Virology*, No. 16, pages 83-97.

Hemaiswarya, S., Doble, M., 2013, Combination of phenylpropanoids with 5-fluorouracil as anti-cancer agent against human cervical cancer (HeLa) cell line, *Phytomedicine*, 20, pp. 151-158.

Hinch, E.J., 1992, *Perturbation Methods*, Cambridge University Press, Cambridge.

Holmes, 1995, *Introduction to Perturbation Methods*, Springer, New York.

Hostetler, K.Y., Rougt, S., Aldern, K.A., et.al, 2006, Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro, *Molecular Cancer Therapeutics*, 5, pp.156-159.

IARC, 2005, *IARC Handbooks of Cancer Prevention,Cervix Cancer Screening*,IARC Press, Lyon.

IARC, 2007, *IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, Volume 90, Human Papillomavirus*,IARC Press, Lyon.

de Jong, A., et.al., 2005, Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell population for adoptive immunotherapy of cervical cancer., *Int. J. Cancer*, Vol. 114, pages 274-282.

Kim, J.J., et.al., 2008, Modeling Cervical Cancer Prevention in Developed Countries, *Vaccine*; 26(suppl 10), K76-K86.

Kirschner, D., Panetta, J.C., 1997, Modeling immunotherapy of tumor-immune interaction, *Journal of Mathematical Biology*, 37 : 235-252.

Kohli M, et.al., 2007, Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK, *British Journal of Cancer*,96(1), 143Ű150. [*PubMed*: 17146475]

Kompas.com., 2008, 52 Juta Perempuan Indonesia Berisiko Kanker Serviks, *http://nasional.kompas.com/read/2008/08/23/07285149*, diakses 14 Mei 2010.

Koyama,et.al.,2007, Staging of Carcinoma of The Uterine Cervix. *Eur Radiol* , 2009-2019.

Kulasingam, S.L., and Myers, E.R., 2003, Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs, *Journal American Medical Association*, Vol 290, No. 6, pages 781-789.

Lowy, D. R, et.al.,1994, Genital Human Papillomavirus Infection, *Proc. Natl. Acad. Sci. USA*. Vol 91. pp. 2436-2440.

Luenberger, D.G., 1979, *Introduction to Dynamic Systems*, John Wiley & Sons, New York.

Majed, Lounes, 2010, A SIS Model for Human Papillomavirus Transmission. http://hal.archives-ouvertes.fr/hal-00555733.

Meinsma, G., 1995, Elementary Proof of the Routh-Hurwitz test, *Systems&Control Letters*, Vol.25, pp:237-242.

Motoyama,S, et.al., 2004, The Role of Human Papilloma Virus in the Molecular Biology of Cervical Carcinoma, *Kobe J. Med. Sci.*, Vol. 50, No. 1, pp. 9-19.

Mougin, C. et.al., 2001, Epidemiology of cervical papillomavirus infections. Recent knowledge, *ncbi.nlm.nih.gov*, 30(20):1017-23.

Nani, F. and Freedman, H.I., 2000, A Mathematical model of cancer treatment by immunotherapy, *Math. Biosci*. 263, pages 159-199.

Nowak M, Bangham CRM (1996) Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 93: 4398–4402

Nowak M, May R (2000) Virus dynamics, mathematical principles of immunology and virology. Oxford University Press, New York

Pecou E .2005, Splitting The Dynamics of Large Biochemical Interaction Networks, *Journal of Theoretical Biology*(232), pages 375-384.

Pecou E., et.al., 2006, A Mathematical Model for Cooper Homeostasis in Enterococcus Hirae, *Mathematical Biosciences* (203), pages 222-239.

Perko,1991, *Differential Equation and Dynamical System*, Springer-Verlag, Berlin.

Prestel, A., Delzell,C.N., 2001, *Positive Polynomials: from Hilbert's 17th Problem to Real Algebra*, Springer-Verlag, Berlin.

Preziosi, L., 2003, *Cancer Modelling and Simulation*, Champman & Hall, Boca Raton.

Rosenberg, S.A., 2001, Progress in human tumour immunology and immunotherapy, *Nature*, Vol.411.

Sanders, G.D. and Taira,A.V., 2003, Cost Efectiveness of Potential Vaccine for Human Papillomavirus, *Emerging Infectious Diseases*, Vol.9, No. 1, pages 37-48.

Schiffman, K., 2003, Natural History of Anogenital Human Papillomavirus Infection and Neoplasia. *Journal of the National Cancer Institute Monographs* No. 31, pages 14-19.

Schoell, W.M.J., et.al., 1999, Generation of Tumor-Specific Cytotoxic T Lymphocytes by Stimulation with HPV Type 16 E7 Peptide-Pulsed Dendritic Cells: An Approach to Immunotherapy of Cervical Cancer, *Gynecologic Oncology* Volume 74, Issue 3, Pages 448-455.

Scholten, K.B.J.et.al., 2005, Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervicalcancer, *Clinical Immunology* Volume 114, Issue 2, Pages 119-129.

Schorge, et.al. 2008,*Williams Gynecology*. Chapter 29. Preinvasive Lesions of the Lower Genital Tract , MC GrawHill's, USA.

Taira, A.V., et.al.,2004, Evaluating Human Papillomavirus Vaccination Programs, *Emerging Infectious Diseases*, Vol. 10, No. 11, pages 915-1923.

Velhust,1990, *Nonlinear Differential Equations and Dynamical Systems*, Springer-Verlag, Berlin .

Widayati, K., 2011, *Tumor Evasion Mechanisms*, The Hallmarks of Cancer: diskusi komprehensif, Fakultas Kedokteran Universitas Gadjah Mada.

Wiggins, S., 2003, *Introduction to Applied Nonlinear Dynamical Systems and Chaos*, Second Edition, Springer-Verlag, New York.

Woodman, 2007, The Natural History of Cervical HPV Infection: Unresolved Issues, *Nat Rev Cancer*, Vol. 7(1): 11-22.

www.whatcauseswarts.co. Download 5 September 2012.

www.steinberg-partner.de. Download 5 September 2012.

www.cancerhelps.com/kanker-serviks.htm. Download 5 September 2012

Wright TC, Ferenczy A (2002) Anatomy and histology of the cervix. In: BlausteinŠs Pathology of The Female Genital Tract, 5th edn. Springer-Verlag, New York, pp 207Ű224.

Yanuar dkk. 2012, Kamus Saku Kedokteran Dorland Ed. 28, EGC Medical Publisher, Jakarta.